Mylan Inc. announced that the US District Court for the District of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline (GSK) in relation to Paroxetine CR, the generic version of GSK's Paxil CR. GSK is now precluded from supplying product to Apotex, which marketed the product as an authorised generic. Mylan had previously been awarded damages in the amount of $106,700,000 by the District Court after a favourable jury verdict in March 2014. Mylan

In addition, the District Court awarded Mylan prejudgment interest and permitted it to take an accounting so that Mylan can determine the amount of additional damages it has suffered since Sept. 30, 2013 as a result of GSK's ongoing breach. All of GSK's post-trial motions were denied.

Mylan is the only company to have successfully developed an FDA-approved generic version of this product.